IE
TAK icon

Israel Englander’s Takeda Pharmaceutical TAK Stock Holding History

Israel Englander’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8M Buy
+1,050,698
New +$17.4M 0.01% 1777
2026
Q1 		– Sell
-890,089
Closed -$13.9M – 6364
2025
Q4 		$13.9M Sell
890,089
-1,666,117
-65% -$23.8M 0.01% 1928
2025
Q3 		$37.4M Sell
2,556,206
-532,463
-17% -$7.91M 0.02% 1079
2025
Q2 		$47.8M Buy
3,088,669
+2,842,012
+1,152% +$42M 0.02% 847
2025
Q1 		$3.67M Sell
246,657
-1,754,246
-88% -$24.6M ﹤0.01% 3175
2024
Q4 		$26.5M Sell
2,000,903
-1,405,703
-41% -$19.3M 0.01% 1293
2024
Q3 		$48.4M Sell
3,406,606
-939,545
-22% -$13.3M 0.02% 834
2024
Q2 		$56.2M Buy
4,346,151
+2,023,707
+87% +$26.8M 0.03% 723
2024
Q1 		$32.3M Sell
2,322,444
-4,170,467
-64% -$60.7M 0.01% 1145
2023
Q4 		$92.7M Buy
6,492,911
+2,730,532
+73% +$38.7M 0.04% 453
2023
Q3 		$58.2M Buy
3,762,379
+677,213
+22% +$10.5M 0.03% 611
2023
Q2 		$48.5M Sell
3,085,166
-754,816
-20% -$12.4M 0.02% 759
2023
Q1 		$63.3M Buy
3,839,982
+1,601,601
+72% +$25.5M 0.04% 562
2022
Q4 		$34.9M Buy
2,238,381
+1,239,382
+124% +$17.3M 0.02% 1011
2022
Q3 		$13M Sell
998,999
-244,423
-20% -$3.4M 0.01% 1828
2022
Q2 		$17.5M Buy
1,243,422
+567,291
+84% +$8.1M 0.01% 1442
2022
Q1 		$9.68M Buy
676,131
+631,280
+1,408% +$9.27M 0.01% 2204
2021
Q4 		$611K Buy
44,851
+29,182
+186% +$409K ﹤0.01% 4871
2021
Q3 		$257K Sell
15,669
-230,243
-94% -$3.87M ﹤0.01% 5926
2021
Q2 		$4.14M Buy
245,912
+108,463
+79% +$1.85M ﹤0.01% 3008
2021
Q1 		$2.51M Buy
+137,449
New +$2.47M ﹤0.01% 3311
2020
Q4 		– Sell
-515,404
Closed -$9.2K – 5572
2020
Q3 		$9.2K Sell
515,404
-358,519
-41% -$6.53M 0.01% 1334
2020
Q2 		$15.7M Sell
873,923
-36,288
-4% -$651K 0.02% 907
2020
Q1 		$13.8M Buy
910,211
+572,940
+170% +$10.4M 0.03% 641
2019
Q4 		$6.65M Buy
+337,271
New +$6.45M 0.01% 1693
2019
Q3 		– Sell
-187,487
Closed -$3.32M – 4546
2019
Q2 		$3.32M Sell
187,487
-1,751,722
-90% -$31.9M 0.01% 2092
2019
Q1 		$39.5M Buy
1,939,209
+1,926,409
+15,050% +$38.8M 0.06% 431
2018
Q4 		$215K Buy
+12,800
New +$216K ﹤0.01% 3371

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Israel Englander's TAK Position: Q2 2026 in Review

Israel Englander opened a new position in Takeda Pharmaceutical (TAK) in Q2 2026: 1,050,698 shares worth $16.8M. The stake represents 0.01% of the portfolio and ranks #1777 among its holdings. This is a return to the name: Israel Englander previously reported a position in TAK as recently as Q4 2025.

Israel Englander first reported a position in TAK in Q4 2018 and has held it in 28 quarters since. The position peaked at $92.7M in Q4 2023. 375 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Israel Englander held 1,050,698 shares of Takeda Pharmaceutical worth $16.8M as of Q2 2026.
  • Takeda Pharmaceutical was a new Israel Englander position in Q2 2026.
  • Takeda Pharmaceutical made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1777 holding.
  • Israel Englander first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 28 quarters since.
  • Israel Englander's Takeda Pharmaceutical position peaked at $92.7M in Q4 2023.
  • 375 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.